A Nanoplatform of Reversing Tumor Immunosuppressive Microenvironment Based on the NIR‐II Gold Hollow Nanorod for the Treatment of Hepatocellular Carcinoma
Small · 2025
DOI: 10.1002/smll.202500144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2025. Verfasst von Xinyuan Cui und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin 2nd Rd, Shanghai, 200025, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Nanotubes, Gold, Liver Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Medicine-Engineering Interdisciplinary Grant at SJTU, National Natural Science Foundation of China.
Abstract (Originalsprache)
Advanced hepatocellular carcinoma (HCC) presents a strongly immunosuppressive tumor microenvironment, which enables tumor cells to evade immune cell attacks and hinder effective drug killing, thereby hindering the achievement of the desired therapeutic effect. In response, a novel nanoplatform‐ AuHNR@γ‐Fe 2 O 3 @Lenvatinib@β‐Glucan (AFLG) with surface modified β‐1,3‐glucan is developed, which exhibits potent immunostimulatory effect and the capability of repolarizing macrophages, to counteract the immunosuppressive conditions present in the tumor microenvironment. Leveraging the hollow structure of gold nanorods, Lenvatinib is efficiently loaded, a first‐line targeted drug for HCC, which effectively inhibits tumor angiogenesis. Additionally, through atomic layer deposition, γ‐Fe 2 O 3 is generated on the hollow gold nanorod surface, endowing it with chemodynamic therapy and magnetic resonance T 2 ‐weighted imaging capabilities while excellently maintaining the gold nanorod's superior photothermal therapy and photoacoustic imaging properties under 1064 nm excitation. These AFLG NPs feature dual‐modal imaging and quadruple‐modal synergistic therapy capabilities, along with their powerful potential in remodeling the immunosuppressive tumor microenvironment, offering an encouraging novel approach for the treatment of hepatocellular carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin 2nd Rd, Shanghai, 200025, P. R. China.
- School of Sensing Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, No. 800 Dongchuan Rd, Shanghai, 200240, P. R. China.
- Department of Radiology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 600 Yishan Rd, Shanghai, 200233, P. R. China.
- Faculty of Medical Imaging Technology, College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, No. 150 Ruijin 2nd Rd, Shanghai, 200025, P. R. China.
ORCID-Profile: Yanlei Liu
Förderung
- Medicine-Engineering Interdisciplinary Grant at SJTU
- National Natural Science Foundation of China
Zitieren
APA
Cui, X., Cao, C., Hao, W., Pan, X., Cao, Y., Fu, Y., Hao, H., Jiao, Y., Lin, S., Cui, S., Li, R., Liu, Y., & Yan, F. (2025). A Nanoplatform of Reversing Tumor Immunosuppressive Microenvironment Based on the NIR‐II Gold Hollow Nanorod for the Treatment of Hepatocellular Carcinoma. Small. https://doi.org/10.1002/smll.202500144
Vancouver
Cui X, Cao C, Hao W, Pan X, Cao Y, Fu Y, et al. A Nanoplatform of Reversing Tumor Immunosuppressive Microenvironment Based on the NIR‐II Gold Hollow Nanorod for the Treatment of Hepatocellular Carcinoma. Small. 2025. doi:10.1002/smll.202500144
BibTeX
@article{Cui2025,
author = {Cui, Xinyuan and Cao, Cheng and Hao, Wanting and Pan, Xinni and Cao, Yu and Fu, Yanfei and Hao, Huifang and Jiao, Yingao and Lin, Shujing and Cui, Shengsheng and Li, Ruokun and Liu, Yanlei and Yan, Fuhua},
title = {A Nanoplatform of Reversing Tumor Immunosuppressive Microenvironment Based on the NIR‐II Gold Hollow Nanorod for the Treatment of Hepatocellular Carcinoma},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202500144}
}
EUVIMED